The company aims to streamline its own lab operations while also enabling distribution of its Alzheimer's tests to outside labs both in the US and abroad.

Zishan Alvi submitted claims to the US Department of Health and Human Services’ Health Resources and Services Administration for COVID-19 tests not performed as billed.

Of the 30 companies in the index, 13 saw their stock prices increase, 15 saw their share prices decline, and two firms' stock prices remained essentially flat.

The Temperature-Activated Generation of Signal (TAGS) technology was developed by Roche for its high-throughput PCR-based instruments.

The Accelerate Arc System and BC kit are used for automated positive blood culture sample preparation for downstream microbial identification.

A hospital, a laboratory, three lab employees, and a referring physician and his office manager have agreed to pay more than $7.2 million dollars to resolve lab fraud allegations.

The firm last week announced it received funding that will allow it to complete development of the test, called Myelo-Scan, by the end of 2026.

Last week, readers were most interested in a story about whether digital pathology is approaching a breakout moment in its adoption curve.

Within three years, the project anticipates at least one test for the early-stage detection of Alzheimer's disease could be ready for commercialization.

NEW YORK – German digital pathology company Mindpeak announced Monday that it has raised $15.3 million in a Series A financing round.

The Cambridge, UK-based firm said that the project will help it to develop its breath-based tests and support the development of tools for breath-based testing.